Management of CMV retinitis in HIV infected patients

Genitourinary Medicine

Volumn 73, Issue 3, 1997, Pages 169-173

  Katlama, Christine ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR; LOBUCAVIR; VALACICLOVIR;

CYTOMEGALOVIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETINITIS; REVIEW;

EID: 79959978865     PISSN: 02664348     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.73.3.169     Document Type: Review

References (32)

1. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated zidovurine. The Zidovudine Epidemiology Study Group. J Infect Dis 1992;166: 1223-7.
2. Peters BS, Beck EJ, Anderson S, Coleman D, Coker R, Main J, et al. Cytomegalovirus infection in AIDS patients. Patterns of disease, response to therapy and trends in survival. J Infect 1991;23:129-37.
3. Salmon D, Lacassin F, Harzic F, Leport C, Perronne C, Bricaire F, et al. Predictive value of cytomegalovirus viremia for occurrence CMV organ involvement in AIDS. J Med Virol 1990;32:150-63.
4. Hansen KK, Rickstein A, Hoffman B, Nomild B, Olofsson S, Mathiesen L, et al. Detection of cytomegalovirus DNA in serum correlates with clinical cytomegalovirus in AIDS. J Infect Dis 1994;170:1271-4.
5. Spector SA, Pilcher M, Lamy P, et al. PCR of plasma for cytomegalovirus DNA identifies HIV-infected persons most likely to benefit from oral ganciclovir prophylaxis 1996;XI Int Conf AIDS, Vancouver (abstract ThB 302).
6. Rasmussen L, Morris S, Zipeto D, Fessel J, Wolitz R, Dowling A, et al. Quantitative of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. J Infect Dis 1995;171:177-82.
7. Oberg B. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol Ther 1989;40:213-85.
8. Ganem D, HHMI and UCSF. KSJ/HHV8 and Kaposi's sarcoma 1997; 4th Conference on Retroviruses and Opportunistic Infections. Washington, 22-26 January (abstract S24-S44).
9. Jacobson MA, Causey D, Polsky B, Hardy D, Chown M, Davis R, et al. A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. J Infect Dis 1993;168:444-8.
10. Katlama C, Dohin E, Caumes E, Cochereau-Massin I, Brancon C, Robinet M, et al. Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-daily regimens. J AIDS 1992;5 (Suppl):S18-S24.
11. Deray G, Martinez F, Katlama C, Levaltier B, Beaufils H, Danis M, et al. Foscarnet nephrotoxiciry: mechanism, incidence and prevention. Am J Nephrol 1989;9:316-21.
12. Benson P, Nahass R, Deresinski S, et al. Safety of oral versus intravenous hydratation during induction therapy with intravenous foscavir (TM) in AIDS patients with CMV infections 1997. 4th Conference on Retroviruses and Opportunistic Infections. Washington, 22-26 January (abstract 299-S31).
13. Kaiser L, Perrin L, Hirshel B, Furrer H, Von Overbeck J, Olman M, et al. Foscarnet decreases human immunodeficiency virus RNA. J Infect Dis 1995;172:225-7.
14. Studies of Ocular Complications of AIDS Research Group in collaboration with AIDS Clinical Trials Group. Mortality in patients acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326: 213-20.
15. Stanat SC, Reardon JE, Erice JA, Jordan MC, Drew WL, Biron KK. Severe resistant cytomegalovirus clinical isolates. Mode of resistance to ganciclovir. Antimicrob Agents Chemother 1991;35:2191-7.
16. Drew WL, Miner RC, Bisch DF, Follansbee SE, Gullett J, Mehalko SG, et al. Prevalence of resistance in patients receiving gangiclovir for serious cytomegalovirus infection. J Infect Dis 1991;163:716-9.
17. Drew WL, Ives D, Lalezari JP, Crumpacker C, Follansbee SE, Benson CA, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995;333:615-20.
18. Oral Ganciclovir European and Australian Cooperative Study Group. Intravenous versus oral ganciclovir European/Australian cooperative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. AIDS 1995;9:471-7.
19. Specter SA. Cytomegalovirus: advances in pathogenesis and improved approaches for treatment and prevention 1997. 4th Conference on Retroviruses and Opportunistic Infections. Washington, 22-26 January (abstract L3-S36).
20. Lalezari JP, Kemper C, Stagg RJ, et al. A randomized, controlled study and efficacy of intravenous cidofovir (CDV, HPMPC) for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. XI Int Conf AIDS, 1996; Vancouver (abstract ThB304).
21. Lalezari JP, Stagg RJ, Kupperman BD, Holland GN, Kremer F, Ives DV, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1997;126:257-63.
22. Flaherty J, Lalezari J, Petty B, et al. Pharmacokinetics and safety of oral lobucavir in cytomegalovirus-infected HIV patients. 4th Conference on Retroviruses and Opportunistic Infections. Washington, 22-26 January 1997; (abstract 302-S31).
23. Lalezari J, Drew L, Jordan C, et al. In vivo anti-CMV activity and safety of oral Lobucavir in HFV-infected patients 1997. 4th Conference on Retroviruses and Opportunistic Infections. Washington, 22-26 January (abstract 301S31).
24. Pauwels R, Balzarini J, Schols D, Baba M, Desmyter J, Rosenberg I, et al. Phosphonylmethoxyethyl purine derivatives, a new class of antiviral human immunodeficiency virus agent. Antimicrob Agents Chemother 1988;32: 1025-30.
25. Balzarini J, Naesens L, Slachmuylders J, Niphuis H, Rosenberg I, Holy A, et al. 9-(2-Phosphonyl-methoxyethy) adeninel (PMEA) effectively inhibits retrovirus replication in vitro and Simian immunodeficiency virus infection in rhesus monkeys. AIDS 1991; 5:21-8.
26. Brown F, Arum I, Francis G, et al. Ganciclovir prodrug (RS-79070) - multiple dose, dose-ranging study with effect of food 1997. 4th Conference on Retroviruses and Opportunistic Infections. Washington, 22-26 January (abstract LB19-S88).
27. Martin DF, Parks DJ, Mellow SD, Ferris FL, Walton RC, Remaley NA, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. Arch Ophthalmol 1994;112:1531-9.
28. The Chiron Ganciclovir Implant Study Group. A randomized controlled multicenter clinical trial of a sustained-released intraocular ganciclovir implant in AIDS patients with CMV retinitis. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995. San Francisco, abstract 215.
29. Studies of Ocular Complication of AIDS Research Group, AIDS Clinical Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch Ophthalmol 1996;114:23-32.
30. Spector SA, McKinley GF, Lalezari JP, Samo T, Andruczk R, Follansbee S, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996;334:1491-7.
31. Brosgart CL, Craig C, Hillman D, et al. Final results from a randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for the prophylaxis of CMV retinal and gastrointestinal mucosal disease 1996. XI Int Conf AIDS, Vancouver (abstract ThB301).
32. Feindberg J, Cooper D, Hurwitz S, et al. Phase III study of valaciclovir (VACV) for cytomegalovirus (CMV) prophylaxis in patients with advanced HIV disease 1995. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco (abstract 1112).